Victory Capital Management
TXMD icon

Victory Capital Management’s TherapeuticsMD TXMD Stock Holding History

Victory Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,142
Closed -$12K – 2751
2022
Q1 		$12K Sell
1,142
-32
-3% -$503 ﹤0.01% 2672
2021
Q4 		$21K Sell
1,174
-29
-2% -$869 ﹤0.01% 2693
2021
Q3 		$45K Buy
1,203
+113
+10% +$5.01K ﹤0.01% 2692
2021
Q2 		$65K Sell
1,090
-44
-4% -$2.67K ﹤0.01% 2651
2021
Q1 		$76K Buy
1,134
+320
+39% +$25K ﹤0.01% 2628
2020
Q4 		$49K Buy
814
+130
+19% +$8.88K ﹤0.01% 2459
2020
Q3 		$54K Buy
684
+8
+1% +$638 ﹤0.01% 2384
2020
Q2 		$42K Sell
676
-697
-51% -$40.6K ﹤0.01% 2407
2020
Q1 		$72K Buy
1,373
+567
+70% +$56.2K ﹤0.01% 2637
2019
Q4 		$98K Buy
806
+250
+45% +$35.9K ﹤0.01% 2545
2019
Q3 		$101K Buy
+556
New +$78.4K ﹤0.01% 2436

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Victory Capital Management's TXMD Position: Q2 2022 in Review

Victory Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 1,142 shares — an estimated $12K sold.

Victory Capital Management first reported a position in TXMD in Q3 2019 and held it in 11 quarters. The position peaked at $101K in Q3 2019. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Victory Capital Management reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Victory Capital Management sold 1,142 TherapeuticsMD shares in Q2 2022, an estimated $12K.
  • Victory Capital Management first reported a position in TherapeuticsMD in Q3 2019 and held it in 11 quarters.
  • Victory Capital Management's TherapeuticsMD position peaked at $101K in Q3 2019.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Victory Capital Management's 13F filing for Q2 2022, filed 1 Aug 2022.